FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2517114388> ?p ?o ?g. }

• W2517114388 abstract "Abstract Introduction: Adult T-cell leukemia-lymphoma (ATL), a distinct subtype of peripheral T-cell lymphoma (PTCL), is caused by human T-lymphotropic virus type-I (HTLV-1). Although rare in the rest of the world, ATL accounts for 25% of PTCL cases diagnosed in Japan, where ATL cases are clustered in areas endemic for HTLV-1 infection. Studies of lenalidomide, an oral immunomodulatory agent that has antiproliferative and direct antineoplastic activity in cutaneous T-cell lymphoma and PTCL, have reported encouraging clinical activity. On the basis of the results from the ATLL-001 dose-finding study of lenalidomide (Uike et al. ASH 2012. Abstract 2737), this multicenter phase II study (ATLL-002) was designed to investigate the efficacy and safety of single-agent lenalidomide in Japanese patients with relapsed ATL. Methods: Patients with relapsed acute, lymphoma, or the unfavorable chronic subtype of ATL who were at least 20 years of age, had ECOG performance status 0-2, no prior allogeneic stem cell transplant, and who had failed at least 1 chemotherapy were included in the study. Patients refractory to their last prior therapy were excluded. Treatment consisted of oral lenalidomide 25 mg/day administered continuously until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR). The secondary endpoints were progression-free survival (PFS), duration of response (DOR), overall survival (OS), and safety. Response was assessed by central review using the criteria proposed by Tsukasaki et al in their international consensus report (J Clin Oncol. 2009;27:453-459.); safety was assessed per NCI CTCAE v4.0 criteria. The estimated number of patients required was 25, for 90% power to detect a lower limit of the 95% confidence interval (CI) exceeding the 5% threshold of ORR, based on the assumptions that the minimum required ORR to a new drug for relapsed or recurrent ATL is 5% and the expected ORR to lenalidomide is 25%. Results: Twenty-six patients were enrolled and received lenalidomide. The median age was 68.5 years (range, 53-81), with 15 (58%) acute, 7 (27%) lymphoma, and 4 (15%) unfavorable chronic type ATL patients. Patients had received a median of 2 (range, 1-4) prior chemotherapeutic or antibody agents for ATL, 11 (42%) of whom received prior mogamulizumab (anti-CCR4 antibody). At a median 3.8-month follow-up, lenalidomide met the primary endpoint by exhibiting an ORR of 42% (11/26; 95% CI, 23-63) (acute 33% [5/15], lymphoma 57% [4/7], unfavorable chronic 50% [2/4]), including 5 (19%) complete responses (CR)/CR unconfirmed (95% CI, 7 to 39; Table 1). Stable disease was 31%, and progressive disease was 27%. The median time to response was 1.9 months (95% CI, 1.8 to 3.7). Although the data were immature at the time of analysis, median DOR for all responders was not reached (NR) (95% CI, 0.5 months to NR), median PFS was 3.8 months (95% CI, 1.9 months to NR), and median OS was 20.3 months (95% CI, 9.1 months to NR). At the time of the data cut-off, 5 (19%) patients remained on lenalidomide treatment. The most common grade 3/4 adverse events (AEs), accounting for at least 10% of all cases, were neutropenia (65%), leukopenia (39%), lymphopenia (39%), thrombocytopenia (23%), anemia (19%), and hypokalemia (12%). Serious AEs were reported in 9 (35%) patients; only thrombocytopenia (2 patients [8%]) was observed in >1 patient. AEs led to dose reduction/interruption in 17 (65%) patients and study discontinuation in 6 (23%). Seven deaths occurred during the study, 6 due to disease progression and 1 due to pneumonia unrelated to lenalidomide treatment. Conclusions: In this multicenter, open-label, phase II study, lenalidomide monotherapy demonstrated a 42% ORR and acceptable tolerability profile. These results support the potential for lenalidomide monotherapy becoming a treatment option for patients with relapsed ATL. Table. Best response to lenalidomide in relapsed ATL ATL type All patients (N = 26) Acute (n = 15) Lymphoma (n = 7) Unfavorable chronic (n = 4) ORR, n (%) 11 (42) 5 (33) 4 (57) 2 (50) CR/CRu, n (%) 5 (19) 3 (20) 2 (29) 0 PR, n (%) 6 (23) 2 (13) 2 (29) 2 (50) SD, n (%) 8 (31) 6 (40) 0 2 (50) PD, n (%) 7 (27) 4 (27) 3 (43) 0 CR, complete response; CRu, CR unconfirmed; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease. Disclosures Fujiwara: Celgene: Honoraria, Other: Research funding to my institution; travel, accommodations, expenses. Off Label Use: Lenalidomide to treat ATL. Ishida:Celgene K.K.: Other: Research Funding to my institution; Bayer Pharma AG: Other: Research Funding to my institution; Kyowa Hakko Kirin Co., LTD: Honoraria, Other: Research Funding to my institution. Moriuchi:Celgene: Other: Research Funding to my institution; travel, accommodations, expenses, Speakers Bureau. Jo:Celgene: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Kyowa Kirin: Honoraria; Nippon Shinyaku: Honoraria. Ishizawa:Kyowa Kirin: Research Funding; Celgin: Research Funding; Janssen: Research Funding; Takeda: Research Funding; GSK: Research Funding; Takeda: Speakers Bureau; Kyowa Kirin: Speakers Bureau; Pfizer: Speakers Bureau; Celgin: Speakers Bureau. Tobinai:Gilead Sciences: Research Funding. Tsukasaki:Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Chugai: Consultancy, Research Funding; Novartis: Research Funding; Pfizer: Research Funding; Mundipharma: Research Funding; Kyowa Kirin Hakkou: Research Funding. Ogura:Mundipharma: Consultancy, Research Funding; MeijiSeika Pharma: Consultancy; Zenyaku: Research Funding; Eisai: Research Funding; Pfizer: Research Funding; Janssen: Research Funding; Celgene: Research Funding; Solaisia: Research Funding. Midorikawa:Celgene K.K.: Employment; Celgene Corporation: Equity Ownership. Ruiz:Celgene K.K.: Employment. Ohtsu:Celgene: Employment, Equity Ownership, Other: travel, accommodations, expenses." @default.
• W2517114388 created "2016-09-16" @default.
• W2517114388 creator A5013146736 @default.
• W2517114388 creator A5015509689 @default.
• W2517114388 creator A5018851305 @default.
• W2517114388 creator A5021620288 @default.
• W2517114388 creator A5033546080 @default.
• W2517114388 creator A5036000764 @default.
• W2517114388 creator A5038817476 @default.
• W2517114388 creator A5039588117 @default.
• W2517114388 creator A5047791149 @default.
• W2517114388 creator A5048061147 @default.
• W2517114388 creator A5049465924 @default.
• W2517114388 creator A5052312620 @default.
• W2517114388 creator A5052778790 @default.
• W2517114388 creator A5056028505 @default.
• W2517114388 creator A5056287200 @default.
• W2517114388 creator A5070304401 @default.
• W2517114388 creator A5075358038 @default.
• W2517114388 creator A5085393435 @default.
• W2517114388 date "2015-12-03" @default.
• W2517114388 modified "2023-09-29" @default.
• W2517114388 title "Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma" @default.
• W2517114388 doi "https://doi.org/10.1182/blood.v126.23.181.181" @default.
• W2517114388 hasPublicationYear "2015" @default.
• W2517114388 type Work @default.
• W2517114388 sameAs 2517114388 @default.
• W2517114388 citedByCount "2" @default.
• W2517114388 countsByYear W25171143882016 @default.
• W2517114388 crossrefType "journal-article" @default.
• W2517114388 hasAuthorship W2517114388A5013146736 @default.
• W2517114388 hasAuthorship W2517114388A5015509689 @default.
• W2517114388 hasAuthorship W2517114388A5018851305 @default.
• W2517114388 hasAuthorship W2517114388A5021620288 @default.
• W2517114388 hasAuthorship W2517114388A5033546080 @default.
• W2517114388 hasAuthorship W2517114388A5036000764 @default.
• W2517114388 hasAuthorship W2517114388A5038817476 @default.
• W2517114388 hasAuthorship W2517114388A5039588117 @default.
• W2517114388 hasAuthorship W2517114388A5047791149 @default.
• W2517114388 hasAuthorship W2517114388A5048061147 @default.
• W2517114388 hasAuthorship W2517114388A5049465924 @default.
• W2517114388 hasAuthorship W2517114388A5052312620 @default.
• W2517114388 hasAuthorship W2517114388A5052778790 @default.
• W2517114388 hasAuthorship W2517114388A5056028505 @default.
• W2517114388 hasAuthorship W2517114388A5056287200 @default.
• W2517114388 hasAuthorship W2517114388A5070304401 @default.
• W2517114388 hasAuthorship W2517114388A5075358038 @default.
• W2517114388 hasAuthorship W2517114388A5085393435 @default.
• W2517114388 hasConcept C126322002 @default.
• W2517114388 hasConcept C143998085 @default.
• W2517114388 hasConcept C2776063141 @default.
• W2517114388 hasConcept C2776364478 @default.
• W2517114388 hasConcept C2778461978 @default.
• W2517114388 hasConcept C2779338263 @default.
• W2517114388 hasConcept C31760486 @default.
• W2517114388 hasConcept C535046627 @default.
• W2517114388 hasConcept C71924100 @default.
• W2517114388 hasConceptScore W2517114388C126322002 @default.
• W2517114388 hasConceptScore W2517114388C143998085 @default.
• W2517114388 hasConceptScore W2517114388C2776063141 @default.
• W2517114388 hasConceptScore W2517114388C2776364478 @default.
• W2517114388 hasConceptScore W2517114388C2778461978 @default.
• W2517114388 hasConceptScore W2517114388C2779338263 @default.
• W2517114388 hasConceptScore W2517114388C31760486 @default.
• W2517114388 hasConceptScore W2517114388C535046627 @default.
• W2517114388 hasConceptScore W2517114388C71924100 @default.
• W2517114388 hasLocation W25171143881 @default.
• W2517114388 hasOpenAccess W2517114388 @default.
• W2517114388 hasPrimaryLocation W25171143881 @default.
• W2517114388 hasRelatedWork W1023665733 @default.
• W2517114388 hasRelatedWork W2296290430 @default.
• W2517114388 hasRelatedWork W2346405952 @default.
• W2517114388 hasRelatedWork W2521775567 @default.
• W2517114388 hasRelatedWork W2563154257 @default.
• W2517114388 hasRelatedWork W2576196958 @default.
• W2517114388 hasRelatedWork W2601214408 @default.
• W2517114388 hasRelatedWork W2605515826 @default.
• W2517114388 hasRelatedWork W2911428551 @default.
• W2517114388 hasRelatedWork W2913479341 @default.
• W2517114388 hasRelatedWork W2954221860 @default.
• W2517114388 hasRelatedWork W2965297464 @default.
• W2517114388 hasRelatedWork W2979710073 @default.
• W2517114388 hasRelatedWork W2980076611 @default.
• W2517114388 hasRelatedWork W2987755656 @default.
• W2517114388 hasRelatedWork W2989071867 @default.
• W2517114388 hasRelatedWork W2991378102 @default.
• W2517114388 hasRelatedWork W3095043345 @default.
• W2517114388 hasRelatedWork W3097836021 @default.
• W2517114388 hasRelatedWork W822712382 @default.
• W2517114388 isParatext "false" @default.
• W2517114388 isRetracted "false" @default.
• W2517114388 magId "2517114388" @default.
• W2517114388 workType "article" @default.